Rheostat Therapeutics inks $23 mln Series A

Cambridge, Massachusetts-based Rheostat Therapeutics, a biotech company focused on treating neurodegeneration, cognition and rare diseases, has raised $23 million in Series A financing. MRLV and AbbVie Ventures led the round.

ManagersNorth AmericaUSHealthcareBriefs